Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 1;5(8):e02194.
doi: 10.1016/j.heliyon.2019.e02194. eCollection 2019 Aug.

The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study

Zainab Nazar Hasan Anber  1 , Basil Oied Mohammed Saleh  2 , Safana Ali Al-Rawi  3
Affiliations

The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study

Zainab Nazar Hasan Anber et al. Heliyon. .

Erratum in

Abstract

Introduction: Breast cancer is the first in ranking among cancers in Iraq. Anthracyclines, cyclophosphamide and taxane are the most active chemotherapeutic regimens used. Anthracyclines induced cardiotoxicity through free radical formation while there is no full understanding about that of cyclophosphamide, but it thought that it may cause direct cardiac muscle damage. While, taxane induced cardiotoxicity through coronary vasoconstriction and oxidative stress. Thus; it is very important to study changes in the cardiac biomarkers as they were the most reliable and sensitive markers associated with cardiotoxicity.

Aim: This research was designed to carry out investigations on the cardiotoxicity effects of these chemotherapeutic drugs in Iraqi patients with breast cancer.

Materials and methods: This research was performed at the Department of Biochemistry, Medicine College, Baghdad University and at the Oncology Department of the Teaching Hospital, Baghdad - Iraq, during the period from May 2018 to October 2018. It was carried out on 56 women with undisturbed menstrual cycle (25-45 years), These women were divided into 3 groups: GI was of 29 women with primary breast cancer without starting any kind of chemotherapy, GII: the same 29 women of GI after finishing 4 cycles of anthracyclines (course 1) and GIII: which involved another 27 women after finishing both course 1 and course 2 (4 cycles of taxanes). Investigations included serum measurements of high sensitive cardiac troponin (hs-cTn), NT-pro-brain natriuretic peptide (NT-ProBNP), and high sensitive- C reactive protein (hs-CRP) by using ELISA technique. The statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 23, when the P-values were less than 0.05, it was considered as significant.

Results: The mean (±SEM) value of the serum hs-CRP levels was decreased significantly in GIII in comparison to both GI (p = 0.004) and GII (p = 0.049) while there was no significant difference between GI and GII. Also, there was no significant difference in the mean (±SEM) value of the serum hs-cTn and the serum NT-PROBNP levels between all groups. The results also showed that there was a significant negative correlation between BMI values and serum NT-proBNP levels in GI (r = -0.435, p = 0.018), GII (r = -0.438, p = 0.018), and GIII (r = -0.384, p = 0.048). In GI, there was also a significant positive correlation between BMI and serum hs-CRP levels (r = 0.395, p = 0.034). Also, there was a significant positive correlation between serum hs-cTn levels and NT-proBNP levels in GI (r = 0.416, p = 0.025) and GII (r = 0.467, p = 0.011). Moreover, there was a significant negative correlation between the serum hs-cTn levels and serum hs- CRP concentrations (r = -0.397, p = 0.040) in GIII.

Conclusion: This study had concluded insignificant changes of cardiac biochemical markers during the chemotherapeutic treatment and that chemotherapy-induced cardiotoxicity is negligible.

Keywords: Cancer research; Chemotherapy; High sensitive -C- reactive protein; High sensitives-cardiac troponin.; Oncology.

PubMed Disclaimer

References

    1. Al-Isawi A.O. Breast cancer in western Iraq: clinicopathological single institution study. Adv. Breast Cancer Res. 2016;5:83–89.
    1. Al-Hashimi M.M., Wang X.J. Breast cancer in Iraq, incidence trends from 2000-2009. Asian Pac. J. Cancer Prev. APJCP. 2014;15:281–286. - PubMed
    1. Kerr D.J., Haller D.G., Verweij J. Principle of chemotherapy. In: Kerr D.J., Haller D.G., Comelis J.H., Baumann M., editors. Oxford Textbook of Oncology. third ed. Oxford University Press; 2016. pp. 186–195.
    1. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart- Gebhart M., Thurlimann B., Senn H.J. Personalizing the treatment of women with early breast cancer: hightlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann. Oncol. 2013;24(9):2206–2223. - PMC - PubMed
    1. Mamounas E.P., Bryant J., Lembersky B., Fehrenbacher L., Sedlacek S.M., Fisher B., Wickerharn D.L., Yothers G., Soran A., Wolmark N. Palitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 2005;23(16):3686–3696. - PubMed